Search

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that Company management will pres

Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S.

Designation is for the treatment of patients with retinitis pigmentosa caused by mutations in exon 13 of the USH2A gene

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov.

Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10 Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020 QR-1123 Investigational New Drug application active for autosomal dominant re